Shanta, K.; Nakayama, K.; Hossain, M.M.; Razia, S.; Ishibashi, T.; Ishikawa, M.; Yamashita, H.; Kanno, K.; Sato, S.; Nakayama, S.;
et al. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. Curr. Oncol. 2022, 29, 4020-4033.
https://doi.org/10.3390/curroncol29060321
AMA Style
Shanta K, Nakayama K, Hossain MM, Razia S, Ishibashi T, Ishikawa M, Yamashita H, Kanno K, Sato S, Nakayama S,
et al. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. Current Oncology. 2022; 29(6):4020-4033.
https://doi.org/10.3390/curroncol29060321
Chicago/Turabian Style
Shanta, Kamrunnahar, Kentaro Nakayama, Mohammad Mahmud Hossain, Sultana Razia, Tomoka Ishibashi, Masako Ishikawa, Hitomi Yamashita, Kosuke Kanno, Seiya Sato, Satoru Nakayama,
and et al. 2022. "Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines" Current Oncology 29, no. 6: 4020-4033.
https://doi.org/10.3390/curroncol29060321
APA Style
Shanta, K., Nakayama, K., Hossain, M. M., Razia, S., Ishibashi, T., Ishikawa, M., Yamashita, H., Kanno, K., Sato, S., Nakayama, S., Otsuki, Y., & Kyo, S.
(2022). Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. Current Oncology, 29(6), 4020-4033.
https://doi.org/10.3390/curroncol29060321